Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 studyCLINICAL & EXPERIMENTAL METASTASISIF3.22024-12-300PRE
Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?BIOMEDICINESIF3.92022-09-2810OAAI
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanomaJOURNAL OF TRANSLATIONAL MEDICINEIF7.52022-04-0523OAAI
Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From ItalyFRONTIERS IN ONCOLOGYIF3.32021-11-0826OAAI
Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the ScalpFRONTIERS IN ONCOLOGYIF3.32021-09-167OAAI
Examining the Relationship between Circulating CD4-CD8-Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic MelanomaCELLSIF5.22021-02-169OAAI
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanomaJOURNAL OF TRANSLATIONAL MEDICINEIF7.52020-12-1012OAAI
Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case ReportFRONTIERS IN ONCOLOGYIF3.32020-07-0711OAAI